ah, yeah, right. In the past, Dr. Hoffmann has always very impressed about the Intercytex guys. Here is the reason in chronological order ...
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
2nd March 2001
Hair loss affects approximately forty percent of men and twenty percent of women aged fifty and over. In the US alone, an estimated 40 million men and 20 million women suffer from baldness and spend $1.5 billion annually on hair loss therapies. Addressing this market, Intercytex is pioneering novel methods for the transplant of dermal hair follicle cells. This technology could be used as a means of regenerating hair, overcoming the need to remove whole hairs from one part of the body and subsequent transplant to another. It also opens the potential for large numbers of hair-generating cells to be expanded in tissue culture and packaged as a one-step solution to hair-loss.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
6th May 2004
Based on emerging positive results from its Phase I study, Intercytex also announced it is planning to initiate Phase II US and UK multi-centre clinical trials of TrichoCyte later this year.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
6th October 2006
Intercytex awarded £1.85m grant from the DTI to automate production of innovative hair regeneration therapy
The grant will be used primarily to develop a dedicated robotic system to support the commercial-scale production of dermal papilla (DP) cells, the main cells involved in hair regeneration and the key component of ICX-TRC. ICX-TRC, a hair regeneration product which has recently entered Phase II clinical trials.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
25th September 2007
Hair regeneration – first 12 patients treated in Phase II trial of ICX-TRC
Post period-end highlights
Preliminary data from Phase II trial of ICX-TRC for hair regeneration shows increased hair counts and good safety profile
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
18th December 2007
In September this year we announced the first results from the current Phase II trial. In the sub-group of subjects (5 in total) whose scalp was pre-stimulated at the time of injection all subjects showed substantial and visible increased hair counts at 6 and/or 12 weeks (13-105%
. We believe this increased hair production is attributable to the interaction between the injected DP cells and the stimulated resident hair producing cells.
A further 5 subjects have now been treated with ICX-TRC using the pre-stimulation technique with 2 more expected in January. By the end of March 2008 we expect to announce preliminary 12 week data on up to 16 subjects in total and preliminary 24 week data on up to 10 subjects.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
18th September 2008
Intercytex Group plc – Interim results for the six months ended 30 June 2008
ICX-TRC - hair regeneration
Data from the Phase II trial shows increase in hair count in 11 out of 14 (79%) evaluable subjects at 24 weeks
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
26th January 2009
Intercytex implements restructuring actions to reduce cash burn
Completion of the Phase II trial of ICX-TRC for hair regeneration continues to be expected at the end of this quarter
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
26th March 2009
ICX-TRC, a hair regeneration product. Phase II trial completed
· Positive data from Phase II trial announced today - increase in hair count in the majority of evaluable subjects observed at 48 weeks.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
The big OOOPS...
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
October 16 2009
Did Intercytex Fail?
"What happened was that the positive results of clinical trials were not as efficient as the lab ones. In other words although promising and exciting, not quite good enough to justify applying for a therapeutic product for the public."
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Anyway, so what can we learn from these "confident and exciting trial results" reports?
Anyway, Aderans bought "OOOPS" a few years ago - and they are still in the "OOOPS phase" ...
... even with the usage of BOTH cell types, epithelial and mesenchymal ("inducer and responder cells") - from the DHT resistent donor area.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
2nd March 2001
Hair loss affects approximately forty percent of men and twenty percent of women aged fifty and over. In the US alone, an estimated 40 million men and 20 million women suffer from baldness and spend $1.5 billion annually on hair loss therapies. Addressing this market, Intercytex is pioneering novel methods for the transplant of dermal hair follicle cells. This technology could be used as a means of regenerating hair, overcoming the need to remove whole hairs from one part of the body and subsequent transplant to another. It also opens the potential for large numbers of hair-generating cells to be expanded in tissue culture and packaged as a one-step solution to hair-loss.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
6th May 2004
Based on emerging positive results from its Phase I study, Intercytex also announced it is planning to initiate Phase II US and UK multi-centre clinical trials of TrichoCyte later this year.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
6th October 2006
Intercytex awarded £1.85m grant from the DTI to automate production of innovative hair regeneration therapy
The grant will be used primarily to develop a dedicated robotic system to support the commercial-scale production of dermal papilla (DP) cells, the main cells involved in hair regeneration and the key component of ICX-TRC. ICX-TRC, a hair regeneration product which has recently entered Phase II clinical trials.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
25th September 2007
Hair regeneration – first 12 patients treated in Phase II trial of ICX-TRC
Post period-end highlights
Preliminary data from Phase II trial of ICX-TRC for hair regeneration shows increased hair counts and good safety profile
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
18th December 2007
In September this year we announced the first results from the current Phase II trial. In the sub-group of subjects (5 in total) whose scalp was pre-stimulated at the time of injection all subjects showed substantial and visible increased hair counts at 6 and/or 12 weeks (13-105%

A further 5 subjects have now been treated with ICX-TRC using the pre-stimulation technique with 2 more expected in January. By the end of March 2008 we expect to announce preliminary 12 week data on up to 16 subjects in total and preliminary 24 week data on up to 10 subjects.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
18th September 2008
Intercytex Group plc – Interim results for the six months ended 30 June 2008
ICX-TRC - hair regeneration
Data from the Phase II trial shows increase in hair count in 11 out of 14 (79%) evaluable subjects at 24 weeks
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
26th January 2009
Intercytex implements restructuring actions to reduce cash burn
Completion of the Phase II trial of ICX-TRC for hair regeneration continues to be expected at the end of this quarter
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
26th March 2009
ICX-TRC, a hair regeneration product. Phase II trial completed
· Positive data from Phase II trial announced today - increase in hair count in the majority of evaluable subjects observed at 48 weeks.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
The big OOOPS...
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
October 16 2009
Did Intercytex Fail?
"What happened was that the positive results of clinical trials were not as efficient as the lab ones. In other words although promising and exciting, not quite good enough to justify applying for a therapeutic product for the public."
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Anyway, so what can we learn from these "confident and exciting trial results" reports?
Anyway, Aderans bought "OOOPS" a few years ago - and they are still in the "OOOPS phase" ...


Why is MPB so complicated!
Comment